Rivulet Media Inc (fka RIVU)

[T_T23]

That is the risk investor in development bio stock take.....if it comes true then 1.0+.....but in the mean time I think we may reach a high of .10-.20, with a higher market capital reached by AMBS....
1) BMSN has actually file for IND (AMBS hasn't even done this), although both Regen and AMBS have their medical report independently peer review (Regen by a rep peer not sure about AMBS) and both have positive animal testing
2) Regen has acquired availabe funding of 20M compare to 3M of AMBS (AMBS are also looking to increase their O/S to acquire these funding)
3) The FDA are looking to approve more IND (they approved the most number of IND last year) that treat life threating diseases such as cancer, Regen is in stem-cell/cancer therapy.
They can always sell the Hemaxellerate drug/patent to the established big bio company, like Regen BioPharma's website has suggested is part of their business.....what is 100M to these company (the current drugs that treat bone marrow earn a revenue of 1B-400M per year)